GB10 eye injection for wet AMD
Part of Eyes & vision clinical trials.
This trial tests an experimental eye injection called GB10 for wet AMD. It is for people who have active leaking blood vessels in the eye and whose vision is between 20/32 and 20/320.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are diagnosed with wet age-related macular degeneration (AMD).
- The eye being treated must have active leaking blood vessels under the retina.
- Your vision in the study eye should be between 20/32 and 20/320 on an eye chart.
- You haven't had an eye injection for wet AMD in the last 3 months, or you've never had one.
- You do not have other serious eye conditions or uncontrolled health problems like high blood pressure or diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
This trial tests a new investigational injection, QL1207H, against an already approved drug (aflibercept) for people with wet age-related macular degeneration, a condition that causes rapid central vision loss. The goal is to see if the new injection works as well or better at stopping further vision loss and possibly improving sight.
This study tests a new injection called RBS-001 compared to the standard treatment Eylea for wet age-related macular degeneration (AMD). The goal is to see if the new drug is as safe and effective at improving vision by reducing fluid and blood vessel growth in the eye.
This trial tests an investigational eye injection called AL-001 for people with wet age-related macular degeneration (AMD) that has responded to previous anti-VEGF treatment. The goal is to see if it improves vision and is safe.
This study tests a new medicine called SKG0106, given as an injection into the eye, for people with wet age-related macular degeneration (AMD). It aims to see if it is safe and effective in treating the leaky blood vessels that cause vision loss.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.